Neuroprotection Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

Mar 2018| TMR311A| Transparency

Report Highlights

Global Neuroprotection Market: Overview

This report on the Neuroprotection market analyzes the current and future scenario of the global market. Increasing incidence of neurological disorders. Product development, drug launches and initiatives for increasing awareness about Neuroprotection are the major drivers of the global Neuroprotection Market.

The Neuroprotection market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product type, application, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Neuroprotection market.

Global Neuroprotection Market: Key Segments

Based on product type, the market has been segmented into Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Metal Ion Chelators, Stimulants, and Others. The application segments have been analyzed based on available approved products for prevention and treatment. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Neuroprotection Market: Regional Outlook

Geographically, the global Neuroprotection market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Spain, Italy, Russia, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global Neuroprotection market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players in the Neuroprotection Market are, Daiichi Sankyo Company, Eli Lilly and Company, Allergan plc, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Biogen Inc., and other prominent players.

The global Neuroprotection market is segmented as given below:

Global Neuroprotection Market Revenue, by Product Type, 2015–2025

Free Radical Trapping Agents (Antioxidants)
Glutamate Antagonists (Anti-Excitotoxic Agents)
Apoptosis Inhibitors
Anti-inflammatory Agents
Neurotrophic Factors (NTFs)
Metal Ion Chelators
Stimulants
Others

Global Neuroprotection Market Revenue, By Application, 2015-2025

Prevention
Treatment

Global Neuroprotection Market Revenue, By Geography, 2015–2025

North America
U.S.
Canada
Europe
Germany
France
U.K.
Spain
Italy
Russia
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC countries
South Africa
Israel
Rest of Middle East & Africa

  • Table 1 : Neuroprotection Market: Pipeline Analysis
  • Table 2 : Neuroprotection Market: Pipeline Analysis
  • Table 3 : Neuroprotection Market: Pipeline Analysis
  • Table 4 : Neuroprotection Market Product mapping
  • Table 5 : Neuroprotection Market Product mapping
  • Table 6 : Neuroprotection Market Mergers & Acquisitions
  • Table 7 : Global Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
  • Table 8 : Global Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
  • Table 9 : Global Neuroprotection Market Size (US$ Mn) Forecast, by Region, 2015–2025
  • Table 10 : North America Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
  • Table 11 : North America Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
  • Table 12 : North America Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
  • Table 13 : Europe Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
  • Table 14 : Europe Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
  • Table 15 : Europe Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
  • Table 16 : Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
  • Table 17 : Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
  • Table 18 : Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
  • Table 19 : Latin America Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
  • Table 20 : Latin America Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
  • Table 21 : Latin America Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
  • Table 22 : Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
  • Table 23 : Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
  • Table 24 : Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
  • Figure 1 : Global Neuroprotection Market Revenue Projections (US$ Mn), 2015–2025
  • Figure 2 : Global Neuroprotection Market Value Share Analysis, Product, 2016 and 2025
  • Figure 3 : Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Free Radical Trapping Agents (Antioxidants), 2015-2025
  • Figure 4 : Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Glutamate Antagonists, 2015-2025
  • Figure 5 : Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Apoptosis Inhibitors, 2015-2025
  • Figure 6 : Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Anti-inflammatory Agents, 2015-2025
  • Figure 7 : Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Neurotrophic Factors (NTFs), 2015-2025
  • Figure 8 : Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Metal Ion Chelators, 2015-2025
  • Figure 9 : Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Stimulants, 2015-2025
  • Figure 10 : Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2015-2025
  • Figure 11 : Global Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
  • Figure 12 : Global Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
  • Figure 13 : Global Neuroprotection Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Prevention, 2015–2025
  • Figure 14 : Global Neuroprotection Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Treatment, 2015–2025
  • Figure 15 : Global Neuroprotection Market Attractiveness Analysis, by Application, 2017–2025
  • Figure 16 : Global Neuroprotection Market Value Share Analysis, by Region, 2016 and 2025
  • Figure 17 : Global Neuroprotection Market Attractiveness Analysis, by Region, 2017–2025
  • Figure 18 : North America Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
  • Figure 19 : North America Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
  • Figure 20 : North America Neuroprotection Market Attractiveness Analysis, by Country
  • Figure 21 : North America Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 22 : North America Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 23 : North America Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
  • Figure 24 : North America Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
  • Figure 25 : North America Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
  • Figure 26 : Europe Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
  • Figure 27 : Europe Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
  • Figure 28 : Europe Neuroprotection Market Attractiveness Analysis, by Country
  • Figure 29 : Europe Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 30 : Europe Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 31 : Europe Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
  • Figure 32 : Europe Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
  • Figure 33 : Europe Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
  • Figure 34 : Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
  • Figure 35 : Asia Pacific Neuroprotection Market Y-o-Y Growth Projection, 2016–2025
  • Figure 36 : Asia Pacific Neuroprotection Market Attractiveness, by Country/Sub-region
  • Figure 37 : Asia Pacific Neuroprotection Market Value Share, by Country/Sub-region, 2016 and 2025
  • Figure 38 : Asia Pacific Neuroprotection Market Value Share, by Product, 2016 and 2025
  • Figure 39 : Asia Pacific Neuroprotection Market Attractiveness, by Product, 2017–2025
  • Figure 40 : Asia Pacific Neuroprotection Market Value Share, by Application, 2016 and 2025
  • Figure 41 : Asia Pacific Neuroprotection Market Attractiveness, by Application, 2017–2025
  • Figure 42 : Latin America Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
  • Figure 43 : Latin America Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
  • Figure 44 : Latin America Neuroprotection Market Attractiveness Analysis, by Country
  • Figure 45 : Latin America Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 46 : Latin America Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
  • Figure 47 : Latin America Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
  • Figure 48 : Latin America Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
  • Figure 49 : Latin America Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
  • Figure 50 : Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
  • Figure 51 : Middle East & Africa Neuroprotection Market Y-o-Y Growth Projection, 2016–2025
  • Figure 52 : Middle East & Africa Neuroprotection Market Attractiveness, by Country/Sub-region
  • Figure 53 : Middle East & Africa Neuroprotection Market Value Share, by Country/Sub-region, 2016 and 2025
  • Figure 54 : Middle East & Africa Neuroprotection Market Value Share, by Product, 2016 and 2025
  • Figure 55 : Middle East & Africa Neuroprotection Market Attractiveness, by Product, 2017–2025
  • Figure 56 : Middle East & Africa Neuroprotection Market Value Share, by Application, 2016 and 2025
  • Figure 57 : Middle East & Africa Neuroprotection Market Attractiveness, by Application, 2017–2025
  • Figure 58 : Global Neuroprotection Market, Company Share, 2016
  • Figure 59 : DAIICHI SANKYO COMPANY, LIMITED R&D Intensity (%) 2015–2016
  • Figure 60 : DAIICHI SANKYO COMPANY, LIMITED Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 61 : DAIICHI SANKYO COMPANY, LIMITED Breakdown of Net Sales, By Region, 2016
  • Figure 62 : Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 63 : Eli Lilly and Company R&D Intensity and Sales – Company Level, 2015–2016
  • Figure 64 : Eli Lilly and Company Breakdown of Net Sales, By Region, 2016
  • Figure 65 : Eli Lilly and Company Breakdown of Net Sales, by Neuroscience products sales, 2016
  • Figure 66 : Allergan plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 67 : Allergan plc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 68 : Allergan plc. Breakdown of Net Sales, by Business Segment, 2016
  • Figure 69 : Allergan plc. Breakdown of Net Sales, by Central Nervous Products Sale, 2016
  • Figure 70 : Dr. Reddy’s Laboratories Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 71 : Dr. Reddy’s Laboratories Ltd. R&D Intensity and Sales & Marketing Intensity US$ Mn – Company Level or Segment Level, 2016–2017
  • Figure 72 : Dr. Reddy’s Laboratories Ltd. Breakdown of Net Sales, by Region, 2017
  • Figure 73 : Dr. Reddy’s Laboratories Ltd. Breakdown of Net Sales, by Business Segments, 2017
  • Figure 74 : Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
  • Figure 75 : Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
  • Figure 76 : Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2016
  • Figure 77 : Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2016
  • Figure 78 : Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
  • Figure 79 : Novartis AG Marketing & Sales, and R&D Expenses, 2015–2016
  • Figure 80 : Novartis AG Breakdown of Net Sales, by Business Segment, 2016
  • Figure 81 : Novartis AG Breakdown of Net Sales, by Region, 2016
  • Figure 82 : AstraZeneca plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 83 : Astra Zeneca R&D Intensity (%) 2015–2016
  • Figure 84 : AstraZeneca plc. Breakdown of Net Sales, by Region (Company Level), 2016
  • Figure 85 : AstraZeneca plc. Breakdown of Net Sales, by Therapy areas 2016
  • Figure 86 : F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
  • Figure 87 : F. Hoffmann-La Roche AG Marketing and R&D Expenses, 2015–2016
  • Figure 88 : F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division, 2016
  • Figure 89 : F. Hoffmann-La Roche AG Breakdown of Net Sales (Pharmaceutical Segment), by Region, 2016
  • Figure 90 : Biogen Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
  • Figure 91 : Biogen R&D Intensity (%), 2015–2016
  • Figure 92 : Biogen Breakdown of Net Sales, by Region, 2016
  • Figure 93 : Biogen Breakdown of Net Sales, by Product, 2016

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report